Replies to post #144408 on Biotech Values

[dav1234]

agree..waiting for open for cheapies..BMY,PFE 4% divi yield

[DewDiligence]

Dr. Topol wonders if something untoward is occurring in the FDA review of Eliquis:

http://blogs.theheart.org/topolog/2012/6/26/there-is-something-strange-about-apixiban

This 5-minute video presents as more of a Topol editorial about the opacity of FDA CRL’s than a bona fide question about Eliquis per se.

My opinion, FWIW, is that BMY/PFE’s statement in #msg-76926354 should be taken at face value—i.e. that the Eliquis CRL can be easily and quickly rectified.

[DewDiligence]

Re: Eliquis NDA resubmission

As I expected (#msg-76926354), the Eliquis CRL issued on 6/25/12 proved to be no big deal for BMY and PFE:

http://news.bms.com/press-release/rd-news/fda-acknowledges-receipt-resubmission-eliquis-apixaban-new-drug-application-re

The new PDUFA date is 3/17/13 (i.e. a 6-month response to the resubmission).